IRINOTECAN HYDROCHLORIDE
Generic: IRINOTECAN HYDROCHLORIDE
Actavis PharmaManufacturer
INTRAVENOUSRoute
IRINOTECAN HYDROCHLORIDEActive Substance
2008-02-27Original Approval
IRINOTECAN HYDROCHLORIDE is FDA application ANDA078589, sponsored by ACTAVIS TOTOWA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2013-09-23
Irinotecan Hydrochloride Injection, 100 mg/5 mL (20 mg/mL), 1 x 5 mL Single Dose Vial per carton, Rx only, Manufactured Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to dete
Class II2013-09-23
Irinotecan Hydrochloride Injection, 40 mg/2 mL (20 mg/mL), 1 x 2 mL Single Dose Vial per carton, Rx only, Manufactured bSuperpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to dete
Class II2020-06-11
Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 2Defective Container: Customer complaints received of a crimp defect while removing the flip-cap duri
Class II2020-06-11
Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 2Defective Container: Customer complaints received of a crimp defect while removing the flip-cap duri
Top Reported Reactions
1
DIARRHOEA
879 reports
2
OFF LABEL USE
708 reports
3
MYELOSUPPRESSION
697 reports
4
NAUSEA
491 reports
5
FEBRILE NEUTROPENIA
485 reports
6
VOMITING
412 reports
7
NEUROPATHY PERIPHERAL
386 reports
8
NEUTROPENIA
385 reports
9
NEOPLASM PROGRESSION
324 reports
10
DISEASE PROGRESSION
320 reports